PARP Inhibitors in Ovarian Cancer.

BACKGROUND Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. METHODS We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on "clinicaltrial.gov" to identify ongoing clinical trials and on "google. com/patents" and "uspto.gov" for recent patents exploring PARPIs in ovarian cancer. RESULTS Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease). CONCLUSION PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

• Publication year

  2018

• Venue

  Recent Patents on Anti-Cancer Drug Discovery

• Publication date

  2018-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1574892813666180305165256PMID 29512470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

  2017cited by this paper
• Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

  2017cited by this paper
• Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

  2017cited by this paper
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors

  2017cited by this paper
• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

  2017cited by this paper
• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2017cited by this paper
• PARP inhibitors: Clinical utility and possibilities of overcoming resistance.

  2017cited by this paper
• Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.

  2017cited by this paper
• Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial

  2017cited by this paper
• Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

  2017cited by this paper
• Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.

  2017cited by this paper
• A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

  2017cited by this paper
• Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

  2017cited by this paper
• Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

  2017cited by this paper
• Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

  2017cited by this paper
• Current status of poly(ADP-ribose) polymerase inhibitors and future directions

  2017cited by this paper
• Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

  2017cited by this paper
• The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).

  2017cited by this paper
• Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.

  2017cited by this paper
• Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

  2016cited by this paper
• An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

  2016cited by this paper
• Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

  2016cited by this paper
• PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

  2016cited by this paper
• Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

  2016cited by this paper
• Functions of PARylation in DNA Damage Repair Pathways

  2016cited by this paper
• Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

  2016cited by this paper
• Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

  2016cited by this paper
• Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

  2016cited by this paper
• Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

  2016cited by this paper
• Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cited by this paper
• An update on PARP inhibitors—moving to the adjuvant setting

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

  2015cited by this paper
• Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

  2015cited by this paper
• A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

  2015cited by this paper
• Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

  2015cited by this paper
• Strategies for combining immunotherapy with radiation for anticancer therapy.

  2015cited by this paper
• PARP inhibitors in ovarian cancer

  2015cited by this paper
• Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

  2015cited by this paper
• 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib

  2015cited by this paper
• Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

  2015cited by this paper
• Phase 1/2 study of oral rucaparib: Final phase 1 results.

  2014cited by this paper
• Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

  2014cited by this paper
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• Non-homologous end joining: emerging themes and unanswered questions.

  2014cited by this paper
• A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

  2014cited by this paper
• PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

  2014cited by this paper
• Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition

  2014cited by this paper
• Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks

  2014cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013cited by this paper
• Replication stress links structural and numerical cancer chromosomal instability

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• Resistance to PARP-Inhibitors in Cancer Therapy

  2013cited by this paper
• First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors

  2013cited by this paper
• Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway

  2013cited by this paper
• Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

  2012cited by this paper
• New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

  2012cited by this paper
• A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy

  2012cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012cited by this paper
• Use of mutation profiles to refine the classification of endometrial carcinomas

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

  2012cited by this paper
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

  2012cited by this paper
• The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

  2011cited by this paper
• PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression

  2011cited by this paper
• Unraveling the mechanism of BRCA2 in homologous recombination

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Secondary mutations of BRCA1/2 and drug resistance

  2011cited by this paper
• PARP-3 and APLF function together to accelerate nonhomologous end-joining.

  2011cited by this paper
• Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.

  2010cited by this paper
• Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

  2010cited by this paper
• Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric Study

  2009cited by this paper
• Development of PARP inhibitors in oncology.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination

  2009cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Hereditary ovarian cancer.

  2009cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper

• Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.

  2026cites this paper
• Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids

  2026cites this paper
• PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers

  2025cites this paper
• Hydnocarpin, a Natural Flavonolignan, Induces the ROS-Mediated Apoptosis of Ovarian Cancer Cells and Reprograms Tumor-Associated Immune Cells

  2025cites this paper
• Acute cardiac dysfunction in patients with ovarian cancer treated with Niraparib due to TFAM mutation: A case series and functional analysis.

  2025cites this paper
• The OvarianTag™ Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer

  2025cites this paper
• Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review

  2025cites this paper
• Development and validation of a risk signature based on disulidptosis-related ferroptosis genes in ovarian cancer.

  2025cites this paper
• Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification

  2025cites this paper
• The Poly (ADP-Ribose) Polymerase-1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study.

  2025cites this paper
• Benchmarking genetic interaction scoring methods for identifying synthetic lethality from combinatorial CRISPR screens

  2025cites this paper
• PARPs in tumor immunology: Signal transduction and combination therapy for the future

  2025cites this paper
• Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer

  2025cites this paper
• Upregulation of NR4A3 increases sensitivity to niraparib in ovarian cancer cells resistant to this drug

  2025cites this paper
• PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining during mitosis

  2025cites this paper
• Precision-Oriented Theophylline-Platinum(IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo.

  2025cites this paper
• Hydrophobic tagging: A promising paradigm for targeted protein degradation

  2025cites this paper
• RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)

  2025cites this paper
• Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

  2024cites this paper
• Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches

  2024cites this paper
• Endometriosis as a risk factor for ovarian cancer: an update on screening, risk reduction, treatment and prognosis

  2024cites this paper
• CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer.

  2024cites this paper
• Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review

  2024cites this paper
• Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms.

  2024cites this paper
• The power and the promise of synthetic lethality for clinical application in cancer treatment.

  2024cites this paper
• 7-Methylguanine Inhibits Colon Cancer Growth in Vivo

  2024cites this paper
• Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC).

  2024cites this paper
• Computer-Aided Drug Discovery Approaches in the Identification of Anticancer Drugs from Natural Products: A Review.

  2024cites this paper
• Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review.

  2024cites this paper
• High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.

  2024cites this paper
• Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors

  2024cites this paper
• Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta‑analysis

  2024cites this paper
• LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1

  2024cites this paper
• Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials

  2024cites this paper
• Clonal evolution and molecular mechanisms of ovarian cancer: a comprehensive review

  2024cites this paper
• Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer

  2024cites this paper
• The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian/fallopian tube cancer

  2024cites this paper
• Mechanism of PARP1 Elongation Reaction Revealed by Molecular Modeling

  2024cites this paper
• The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis

  2023cites this paper
• Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer

  2023cites this paper
• Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems

  2023cites this paper
• Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

  2023cites this paper
• Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling

  2023cites this paper
• Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

  2023cites this paper
• Transporter‑mediated drug‑drug interactions involving poly (ADP‑ribose) polymerase inhibitors (Review).

  2023cites this paper
• Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study

  2023cites this paper
• Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer

  2023cites this paper
• Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens

  2023cites this paper
• Natural Guanine Derivatives Exert PARP-Inhibitory and Cytoprotective Effects in a Model of Cardiomyocyte Damage under Oxidative Stress

  2023cites this paper
• Association between Preoperative 18-FDG PET-CT SUVmax and Next-Generation Sequencing Results in Postoperative Ovarian Malignant Tissue in Patients with Advanced Ovarian Cancer

  2023cites this paper
• Poly(ADP-ribose) Polymerase Inhibitor Olaparib in the Treatment of Ovarian Cancer: A Comprehensive Review of Current Literature

  2023cites this paper
• New use of preoperative fibrinogen in ovarian cancer management

  2023cites this paper
• Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy

  2023cites this paper
• PARP inhibitor-related haemorrhages: What does the real-world study say?

  2023cites this paper
• The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking

  2023cites this paper
• Targeting TRIP13 for overcoming anticancer drug resistance (Review)

  2023cites this paper
• Probing the Cytotoxic Signaling Induced by Eupenifeldin in Ovarian Cancer Models.

  2023cites this paper
• Molecular mechanisms of cisplatin resistance in ovarian cancer

  2023cites this paper
• Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer

  2023cites this paper
• BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis

  2023cites this paper
• Gentian Violet Inhibits Cell Proliferation through Induction of Apoptosis in Ovarian Cancer Cells

  2023cites this paper
• Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer

  2023cites this paper
• PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway

  2023cites this paper
• A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies

  2023cites this paper
• ETS transcription factor ELK3 in human cancers: An emerging therapeutic target.

  2023cites this paper
• Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.

  2023cites this paper
• Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway

  2023cites this paper
• Breast cancer in the era of precision medicine

  2022cites this paper
• Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity

  2022cites this paper
• PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.

  2022cites this paper
• PARP inhibition in breast cancer: progress made and future hopes

  2022cites this paper
• Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Surgery in platinum-resistant recurrent epithelial ovarian carcinoma

  2022cites this paper
• Clinical Utility of Next-generation Sequencing in Real-world Cases: A Single-institution Study of Nine Cases

  2022cites this paper
• The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways

  2022cites this paper
• Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma

  2022cites this paper
• Maintenance niraparib therapy for patients with relapsed platinum sensitive ovarian cancer: experience at a south coast network

  2022cites this paper
• Recent Progress of the research on the benzimidazole PARP-1 inhibitors.

  2022cites this paper
• ATR Inhibitors in Platinum-Resistant Ovarian Cancer

  2022cites this paper
• Inhibitory Effects of 7-Methylguanine and Its Metabolite 8-Hydroxy-7-Methylguanine on Human Poly(ADP-Ribose) Polymerase 1

  2022cites this paper
• Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.

  2022cites this paper
• m6A‐related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma

  2022cites this paper
• DDDT_A_387920 3947..3955

  2022cites this paper
• The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1.

  2022cites this paper
• A deep learning model trained on only eight whole-slide images accurately segments tumors: wise data use versus big data

  2022cites this paper
• Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality

  2022cites this paper
• Circular RNA hsa_circ_0000144 aggravates ovarian Cancer progression by regulating ELK3 via sponging miR-610

  2022cites this paper
• Potential Targeted Therapies in Ovarian Cancer

  2022cites this paper
• Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation

  2022cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

  2022cites this paper
• Systemische Therapie und zielgerichtete Erhaltungstherapie in der Primärsituation beim high- und low-grade Ovarialkarzinom

  2022cites this paper
• The effect of calycosin-7-O-β-D-glucoside and its synergistic augmentation of cisplatin-induced apoptosis in SK-OV-3 cells.

  2022cites this paper
• Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!

  2022cites this paper
• RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors

  2022cites this paper
• Switching PARP inhibitors as an effective approach for niraparib‐induced erythema multiforme

  2022cites this paper
• Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment

  2022cites this paper
• Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

  2021cites this paper
• High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer.

  2021cites this paper
• CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer

  2021cites this paper
• The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?

  2021cites this paper